8-K Announcements
6Material company update
May 21, 2026·SEC
Material company update
May 21, 2026·SEC
Material company update
Mar 30, 2026·SEC
Immix Biopharma, Inc.(IMMX)Earnings, Financials & Key Ratios
IMMX•NASDAQ
Price updated Jun 11, 2026
AboutImmix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.Show more
- Revenue$0
- EBITDA-$27M-19.0%
- Net Income-$29M-36.2%
- EPS (Diluted)-0.89-17.1%
- ROE-55%+62.5%
- ROIC-2169.79%
- Debt/Equity0.01-85.9%
IMMX Key Insights
Immix Biopharma, Inc. (IMMX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 94 (top 6%)
✗Weaknesses
- ✗Profits declining 91.3% over 5 years
- ✗Shares diluted 16.5% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when IMMX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
IMMX Price & Volume
Immix Biopharma, Inc. (IMMX) stock price & volume — 10-year historical chart
Loading chart...
IMMX Growth Metrics
Immix Biopharma, Inc. (IMMX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-67.41%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-29.58%
Return on Capital
10 Years-75.87%
5 Years-75.87%
3 Years-102.33%
Last Year-49.93%
IMMX Recent Earnings
Immix Biopharma, Inc. (IMMX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)
Q2 2026Latest
May 7, 2026EPS
$0.18
Est $0.18
+0.3%
Revenue
—
Q2 2026
Mar 25, 2026EPS
$0.27
Est $0.21
-28.6%
Revenue
—
Q4 2025
Nov 7, 2025EPS
$0.24
Est $0.19
-26.3%
Revenue
—
Q3 2025
Aug 8, 2025EPS
$0.22
Est $0.21
-4.8%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.18vs $0.18+0.3% | — |
| Q2 2026 | Mar 25, 2026 | $0.27vs $0.21-28.6% | — |
| Q4 2025 | Nov 7, 2025 | $0.24vs $0.19-26.3% | — |
| Q3 2025 | Aug 8, 2025 | $0.22vs $0.21-4.8% | — |
Based on last 12 quarters of dataView full earnings history →
IMMX Peer Comparison
Immix Biopharma, Inc. (IMMX) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 CABA | 490.79M | 3.01 | -1.84 | -131.58% | 0.24 | |||
 KYMR | 6.77B | 82.96 | -22.48 | -16.72% | -6.12% | -25.02% | 0.05 | |
 IMVT | 6.75B | 32.88 | -11.87 | -68.16% | 0.00 | |||
 ARQT | 3.08B | 24.59 | -189.15 | 91.34% | -0.57% | -1.41% | 0.03 | |
 PRAX | 7.16B | 247.98 | -18.40 | -100% | -43.02% | 0.00 | ||
 FATE | 229.62M | 1.97 | -1.71 | -51.24% | -20.57% | -58.89% | 0.38 | |
 NTLA | 1.39B | 12.35 | -3.24 | 16.92% | -5.97% | -57.27% | 0.14 | |
 BEAM | 3.02B | 29.41 | -36.31 | 120.01% | -49.17% | -5.89% | 0.24 |
Compare IMMX vs Peers
Immix Biopharma, Inc. (IMMX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
IMMX Income Statement
Immix Biopharma, Inc. (IMMX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | - | - | - | - |
Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 364.5K | 130.77K |
COGS % of Revenue | - | - | - | - | - | - | - | - |
Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | -364.5K▲ 0% | -130.77K▲ 0% |
Gross Margin % | - | - | - | - | - | - | - | - |
Gross Profit Growth % | - | - | - | - | - | - | - | - |
Operating Expenses | 842.5K | 453.85K | 1.35M | 8.22M | 16.14M | 22.67M | 26.85M | 35.95M |
OpEx % of Revenue | - | - | - | - | - | - | - | - |
Selling, General & Admin | 259.34K | 205.7K | 1.23M | 4.02M | 7.41M | 11.38M | 13.7M | 15.81M |
SG&A % of Revenue | - | - | - | - | - | - | - | - |
Research & Development | 583.16K | 248.15K | 126.53K | 4.2M | 8.74M | 11.29M | 16.26M | 20.26M |
R&D % of Revenue | - | - | - | - | - | - | - | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | -3.11M | -125.76K |
Operating Income | -842.5K▲ 0% | -453.85K▲ 46.1% | -1.35M▼ 197.9% | -8.22M▼ 507.9% | -16.14M▼ 96.4% | -22.67M▼ 40.5% | -27.21M▼ 20.0% | -36.08M▲ 0% |
Operating Margin % | - | - | - | - | - | - | - | - |
Operating Income Growth % | - | 46.13% | -197.9% | -507.9% | -96.39% | -40.48% | -20.01% | - |
EBITDA | -841.42K | -451.53K | -1.35M | -8.22M | -16.14M | -22.56M | -26.85M | -35.68M |
EBITDA Margin % | - | - | - | - | - | - | - | - |
EBITDA Growth % | - | 46.34% | -198.88% | -508.86% | -96.37% | -39.81% | -19% | -65.08% |
D&A (Non-Cash Add-back) | 1.08K | 2.32K | 2.47K | 2.13K | 5.47K | 115.39K | 364.5K | 398.22K |
EBIT | -842.5K | -453.85K | -24.2M | -8.22M | -16.14M | -22.67M | -27.21M | -36M |
Net Interest Income | -109.98K | -101.98K | -179.85K | -497 | 572.01K | 1.02M | 555.53K | 1.12M |
Interest Income | 0 | 0 | 0 | 0 | 572.01K | 1.02M | 555.53K | 1.12M |
Interest Expense | 109.98K | 101.98K | 179.85K | 497 | 0 | 0 | 0 | 0 |
Other Income/Expense | -109.76K | -676.46K | -23.03M | -497 | 572.01K | 1.02M | -2.19M | 1.13M |
Pretax Income | -952.26K▲ 0% | -1.13M▼ 18.7% | -24.38M▼ 2056.7% | -8.22M▲ 66.3% | -15.57M▼ 89.4% | -21.66M▼ 39.1% | -29.4M▼ 35.8% | -34.95M▲ 0% |
Pretax Margin % | - | - | - | - | - | - | - | - |
Income Tax | 20.55K | 17.55K | 6.01K | 10.27K | 26.41K | 41.04K | 37.72K | 27.9K |
Effective Tax Rate % | -2.16% | -1.55% | -0.02% | -0.12% | -0.17% | -0.19% | -0.13% | -0.08% |
Net Income | -972.81K▲ 0% | -1.15M▼ 18.0% | -24.38M▼ 2024.3% | -8.23M▲ 66.2% | -15.43M▼ 87.4% | -21.61M▼ 40.1% | -29.44M▼ 36.2% | -34.98M▲ 0% |
Net Margin % | - | - | - | - | - | - | - | - |
Net Income Growth % | - | -17.99% | -2024.28% | 66.25% | -87.44% | -40.11% | -36.21% | -67.41% |
Net Income (Continuing) | -972.81K | -1.15M | -24.38M | -8.23M | -15.6M | -21.7M | -29.44M | -34.98M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | -201.74K | 0 | 0 | 0 |
EPS (Diluted) | -0.29▲ 0% | -0.15▲ 48.3% | -6.64▼ 4326.7% | -0.59▲ 91.1% | -0.89▼ 50.8% | -0.76▲ 14.6% | -0.89▼ 17.1% | -0.91▲ 0% |
EPS Growth % | - | 48.28% | -4326.67% | 91.11% | -50.85% | 14.61% | -17.11% | -29.58% |
EPS (Basic) | -0.29 | -0.15 | -6.64 | -0.59 | -0.89 | -0.76 | -0.89 | - |
Diluted Shares Outstanding | 3.38M | 7.77M | 3.67M | 13.89M | 17.34M | 28.29M | 32.97M | 38.29M |
Basic Shares Outstanding | 3.38M | 7.77M | 3.67M | 13.89M | 17.34M | 28.29M | 32.97M | 38.29M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - |
IMMX Balance Sheet
Immix Biopharma, Inc. (IMMX) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Total Current Assets | 933.26K | 532.24K | 18.19M | 14.9M | 19.79M | 20.2M | 101.24M | 92.27M |
Cash & Short-Term Investments | 734.01K | 391.09K | 17.64M | 13.44M | 17.51M | 17.68M | 100.41M | 90.58M |
Cash Only | 734.01K | 391.09K | 17.64M | 13.44M | 17.51M | 17.68M | 93.93M | 79.25M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 6.48M | 11.33M |
Accounts Receivable | 175.75K | 127.44K | 25.72K | 255.71K | 1.17M | 1.97M | 0 | 0 |
Days Sales Outstanding | - | - | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 0 | 78.07K | 44.58K | 32.27K | 828.33K | 1.7M |
Total Non-Current Assets | 9.68K | 7.36K | 5.7K | 10.28K | 137.41K | 2.75M | 3.6M | 3.54M |
Property, Plant & Equipment | 9.68K | 7.36K | 5.7K | 3.56K | 50.18K | 2.73M | 3.49M | 3.36M |
Fixed Asset Turnover | - | - | - | - | - | - | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 6.72K | 87.23K | 20.42K | 114.05K | 185.14K |
Total Assets | 942.94K▲ 0% | 539.6K▼ 42.8% | 18.19M▲ 3271.4% | 14.91M▼ 18.1% | 19.93M▲ 33.7% | 22.95M▲ 15.2% | 104.84M▲ 356.9% | 95.82M▲ 0% |
Asset Turnover | - | - | - | - | - | - | - | 0.00x |
Asset Growth % | - | -42.78% | 3271.42% | -18.05% | 33.65% | 15.17% | 356.86% | 672.63% |
Total Current Liabilities | 4.59M | 5.27M | 202.04K | 1.27M | 3.72M | 8.69M | 10.11M | 10.54M |
Accounts Payable | 247.54K | 252.34K | 142.94K | 143.07K | 1.43M | 5.39M | 0 | 0 |
Days Payables Outstanding | - | - | - | - | - | - | - | 9.54K |
Short-Term Debt | 4.1M | 4.1M | 50K | 0 | 0 | 0 | 139.34K | 125.39K |
Deferred Revenue (Current) | 0 | 342.84K | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 232.16K | 0 | 0 | 0 | 658.16K | 9.97M | 10.41M |
Current Ratio | 0.20x | 0.10x | 90.01x | 11.70x | 5.32x | 2.33x | 10.01x | 8.76x |
Quick Ratio | 0.20x | 0.10x | 90.01x | 11.70x | 5.32x | 2.33x | 10.01x | 8.76x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 0 | 0 | 0 | 475K | 0 | 1.01M | 933.63K | 912.34K |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 933.63K | 912.34K |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 1.01M | 0 | 1.94M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 475K | 0 | 0 | 0 | 0 |
Total Liabilities | 4.59M | 5.27M | 202.04K | 1.75M | 3.72M | 9.7M | 11.04M | 11.45M |
Total Debt | 4.1M | 4.1M | 50K | 0 | 0 | 1.07M | 1.07M | 1.04M |
Net Debt | 3.37M | 3.71M | -17.59M | -13.44M | -17.51M | -16.61M | -92.86M | -78.21M |
Debt / Equity | - | - | 0.00x | - | - | 0.08x | 0.01x | 0.01x |
Debt / EBITDA | - | - | - | - | - | - | - | -0.03x |
Net Debt / EBITDA | - | - | - | - | - | - | - | 2.19x |
Interest Coverage | -7.66x | -4.45x | -134.54x | -16537.12x | - | - | - | - |
Total Equity | -3.65M▲ 0% | -4.73M▼ 29.7% | 17.99M▲ 480.3% | 13.16M▼ 26.8% | 16.2M▲ 23.1% | 13.25M▼ 18.2% | 93.8M▲ 607.8% | 84.36M▲ 0% |
Equity Growth % | - | -29.73% | 480.29% | -26.85% | 23.13% | -18.22% | 607.83% | 1253.78% |
Book Value per Share | -1.08 | -0.61 | 4.90 | 0.95 | 0.93 | 0.47 | 2.85 | 2.20 |
Total Shareholders' Equity | -3.65M | -4.73M | 17.99M | 13.16M | 16.41M | 13.25M | 93.8M | 84.36M |
Common Stock | 338 | 338 | 1.32K | 1.4K | 2K | 2.76K | 5.3K | 5.31K |
Retained Earnings | -4.22M | -5.37M | -29.76M | -37.99M | -53.41M | -75.02M | -104.46M | -114.55M |
Treasury Stock | 0 | 0 | 0 | -99.96K | -99.96K | -99.96K | 0 | 0 |
Accumulated OCI | 68.22K | 131.86K | 125.41K | 87.02K | 134.67K | -1.06K | 60.16K | 105.64K |
Minority Interest | 0 | 0 | 0 | 0 | -201.74K | 0 | 0 | 0 |
IMMX Cash Flow Statement
Immix Biopharma, Inc. (IMMX) cash flow — operating, investing & free cash flow history
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Cash from Operations | -790.03K | -404.69K | -1.59M | -7.41M | -11.37M | -14.6M | -23.93M | -32.07M |
Operating CF Margin % | - | - | - | - | - | - | - | - |
Operating CF Growth % | - | 48.77% | -292.72% | -366.13% | -53.5% | -28.35% | -63.96% | -1177.68% |
Net Income | -972.81K | -1.15M | -24.38M | -8.23M | -15.6M | -21.61M | -29.44M | -34.98M |
Depreciation & Amortization | 1.08K | 2.32K | 2.47K | 2.13K | 5.47K | 115.39K | 364.5K | 436.09K |
Stock-Based Compensation | 0 | 0 | 218.98K | 624.07K | 2.57M | 0 | 2.44M | 2.15M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 0 | 575K | 22.96M | 0 | 0 | 2.94M | 0 | 23.5K |
Working Capital Changes | 181.7K | 165.85K | -391.04K | 195.21K | 1.65M | 3.97M | 2.7M | 301.74K |
Change in Receivables | -36.29K | 58.49K | 97.67K | -236.38K | -893.4K | -971.53K | 2.06M | 55.2K |
Change in Inventory | 36.29K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 122.95K | -3.83K | -106.06K | 1.13M | 2.43M | 4.4M | 1.03M | -358.66K |
Cash from Investing | -7.31K | 0 | -802 | 0 | -52.09K | -1.18M | -7.21M | -11.95M |
Capital Expenditures | -7.31K | 0 | -802 | 0 | -52.09K | -1.18M | -732.92K | -697.7K |
CapEx % of Revenue | - | - | - | - | - | - | - | - |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 1.05M | 0 | 18.85M | 3.23M | 15.46M | 15.95M | 107.39M | 107.35M |
Debt Issued (Net) | 1.05M | 0 | 200K | -50K | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 0 | 0 | 18.65M | 3.29M | 15.7M | 15.95M | 107.39M | 107.51M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | -99.96K | 0 | 0 | 0 | 0 |
Other Financing | 0 | 0 | 0 | -6.72K | -232K | 0 | 0 | -160.41K |
Net Change in Cash | 271.69K▲ 0% | -342.93K▼ 226.2% | 17.25M▲ 5131.2% | -4.21M▼ 124.4% | 4.07M▲ 196.8% | 172.16K▼ 95.8% | 76.25M▲ 44187.5% | 63.33M▲ 0% |
Free Cash Flow | -797.34K▲ 0% | -404.69K▲ 49.2% | -1.59M▼ 292.9% | -7.41M▼ 365.9% | -11.42M▼ 54.2% | -15.77M▼ 38.1% | -24.66M▼ 56.4% | -32.77M▲ 0% |
FCF Margin % | - | - | - | - | - | - | - | - |
FCF Growth % | - | 49.24% | -292.92% | -365.9% | -54.2% | -38.07% | -56.37% | -144.61% |
FCF per Share | -0.24 | -0.05 | -0.43 | -0.53 | -0.66 | -0.56 | -0.75 | -0.86 |
FCF Conversion (FCF/Net Income) | 0.81x | 0.35x | 0.07x | 0.90x | 0.74x | 0.68x | 0.81x | 0.94x |
Interest Paid | 67 | 899 | 1.54K | 9.6K | 0 | 0 | 0 | 0 |
Taxes Paid | 20.55K | 17.55K | 0 | 0 | 0 | 0 | 0 | 16.64K |
IMMX Key Ratios
Immix Biopharma, Inc. (IMMX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -367.8% | -52.84% | -105.07% | -146.76% | -55% | -73.23% |
| Return on Invested Capital (ROIC) | - | -256.34% | -10389.53% | - | - | -2169.79% | 1995% |
| Debt / Equity | - | 0.00x | - | - | 0.08x | 0.01x | 0.01x |
| Interest Coverage | -4.45x | -134.54x | -16537.12x | - | - | - | - |
| FCF Conversion | 0.35x | 0.07x | 0.90x | 0.74x | 0.68x | 0.81x | 0.94x |
Related:IMMX Dividend History·IMMX Revenue History·IMMX Price History·IMMX P/E History·IMMX Financial Ratios·IMMX Institutional Holders
IMMX SEC Filings & Documents
Immix Biopharma, Inc. (IMMX) SEC filings — annual & quarterly reports (10-K, 10-Q)
IMMX Frequently Asked Questions
Immix Biopharma, Inc. (IMMX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Immix Biopharma, Inc. (IMMX) grew revenue by 0.0% over the past year. Growth has been modest.
Immix Biopharma, Inc. (IMMX) reported a net loss of $35.0M for fiscal year 2025.
Dividend & Returns
Immix Biopharma, Inc. (IMMX) has a return on equity (ROE) of -55.0%. Negative ROE indicates the company is unprofitable.
Immix Biopharma, Inc. (IMMX) had negative free cash flow of $32.8M in fiscal year 2025, likely due to heavy capital investments.